A study from researchers at the University of Michigan and the University of California San Diego has shed light on a ...

Stay up to date on the latest AI technology advancements and learn about the challenges and opportunities AI presents now and ...

"The platform's key advantage lies in its ability to encapsulate the antibody within the NanoGel during circulation and ensure its controlled release in the bone metastatic niche ... therapy's ...

Researchers at the University of Iowa found that adding high-dose IV vitamin C to chemotherapy helped increase survival in ...

Flatiron Health today announced their planned presence at this year’s San Antonio Breast Cancer Symposium (SABCS), including four accepted abstracts for poster presentation and a Flatiron ...

Researchers at Baylor College of Medicine and Rice University have received a $2.3 million Breakthrough Award from the ...

Linda D’Addario, a cancer survivor, now mentors others through Cancer Hope Network, a program now available at five area ...

Schad, a compassionate soul and dedicated community member, passed away on Friday, November 29, 2024, at the age of 50 at CHP ...

Olema Oncology plans to start a Phase III trial studying palazestrant with a CDK4/6 inhibitor from Novartis in mid-2025.

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, ...

Olema Oncology has announced that it has entered into a clinical trial collaboration and supply agreement with Novartis to ...

The Data Safety Monitoring Board (DSMB) stated no safety concerns, and recommended continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT™ ...